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Clinical Investigation
Clinical and Hemodynamic Correlates and Prognostic Value of
VE/VCO2 Slope in Patients With Heart Failure With Preserved
Ejection Fraction and Pulmonary Hypertension
SEBASTIAAN H. C. KLAASSEN, BSc, LICETTE C. Y. LIU, MD, PhD, YORAN M. HUMMEL, PhD, KEVIN DAMMAN, MD, PhD,
PETER VAN DER MEER, MD, PhD, ADRIAAN A. VOORS, MD, PhD, ELKE S. HOENDERMIS, MD, PhD, AND
DIRK J. VAN VELDHUISEN, MD, PhD
Groningen, The Netherlands
ABSTRACT
Background: Impaired exercise capacity is one of the hallmarks of heart failure with preserved ejection
fraction (HFpEF), but the clinical and hemodynamic correlates and prognostic value of exercise testing in
patients with HFpEF is unknown.
Methods: Patients with HFpEF (left ventricular ejection fraction [LVEF] ≥45%) and pulmonary hyper-
tension underwent cardiopulmonary exercise test (CPX) to measure maximal (peak VO2) and submaximal
(ventilatory equivalent for carbon dioxide [VE/VCO2] slope) exercise capacity. In addition, right heart cath-
eterization was performed. Patients were grouped in tertiles based on the VE/VCO2 slope. Univariate and
multivariate regression analyses were performed. A Cox regression analysis was performed to determine
the mortality during follow-up.
Results: We studied 88 patients: mean age 73 ± 9 years, 67% female, mean LVEF 58%, median N-terminal
pro–B-type natriuretic peptide (NT-proBNP) 840 (interquartile range 411–1938) ng/L. Patients in the highest
VE/VCO2 tertile had the most severe HF, as reflected in higher New York Heart Association functional class
and higher NT-proBNP plasma levels (all P < .05 for trend), whereas LVEF was similar between the groups.
Multivariable regression analysis with backward elimination on invasive hemodynamic measurements showed
that VE/VCO2 slope was independently associated with pulmonary vascular resistance (PVR). Cox regres-
sion analysis showed that increased VE/VCO2 slope (but not peak VO2) was independently associated with
increased mortality.
Conclusion: Increased VE/VCO2 slope was associated with more severe disease and higher
PVR and was independently associated with increased mortality in patients with HFpEF. (J Cardiac Fail
2017;23:777–782)
Key Words: VE/VCO2 slope, heart failure with preserved ejection fraction, cardiopulmonary exercise test.
Approximately 50% of patients with heart failure have a
preserved ejection fraction (HFpEF).1 HFpEF is associated
with high morbidity and mortality, and no evidence-based
therapies are available for these patients.2 Increased pulmo-
nary arterial pressure is another important factor that is
associated with the severity of HFpEF and consequently results
in higher mortality.3
In addition to standard diagnostic tests, cardiopulmonary
exercise testing (CPX) provides useful information regard-
ing the clinical condition of patients.4 Although peak VO2
is the criterion standard in patients with heart failure, HFpEF
patients often do not achieve peak VO2 owing to elderly
age and the presence of multiple comorbidities.5 The VE/
VCO2 slope can be determined from submaximal exercise
testing. Measurement of the slope of VE versus VCO2 (VE/
VCO2 slope) during incremental exercise below the ventilatory
compensation point is a prognostic indicator in patients
with heart failure (HF) with reduced ejection fraction (HFrEF),6
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wbut the clinical characteristics and prognostic value of
increased VE/VCO2 slope in patients with HFpEF is unknown.7
In the present study, we investigated the VE/VCO2 slope
during CPX in HFpEF patients to reveal its association
with both invasive and noninvasive predictors and clinical
outcome.
Methods
Study Design and Patient Selection
From October 2011 to September 2014, we retrospec-
tively identified 102 patients with HFpEF based on heart
failure symptoms (New York Heart Association [NYHA]
functional class ≥II), left ventricular ejection fraction (LVEF)
≥45%, and signs of pulmonary hypertension on an
earlier echocardiogram who were referred to the catheter-
ization laboratory for routine left- and right-sided cardiac
catheterization. At the same time as the catheterization,
echocardiographic assessments were performed. Within 1
week after catheterization, exercise tolerance tests on a
treadmill were carried out when patients were capable to do
an exercise test, and during the exercise the VO2 max test
was performed. After these screening tests, a subset
of the study patients were recruited for a single-center
prospective randomized placebo-controlled trial investigat-
ing the effects of sildenafil in HFpEF with pulmonary
hypertension.8 Fifty-two of these patients were included
in this trial, of which 26 were allocated to the sildenafil
group.
Study Procedures
In all of the screened patients (n = 102), clinical and
laboratory assessments were conducted regarding NYHA
functional class, heart rhythm, medication usage, and
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and
electrolyte plasma levels. In clinically stable patients, right-
sided heart catheterization (HC) and simultaneous
echocardiography were performed. These tests were ex-
ecuted by the same cardiologist and ultrasound technician
in all of the patients. Echocardiographic parameters LV
wall thickness, mitral valve velocities, tissue Doppler pa-
rameters, and systolic and diastolic ventricular end volumes
were collected. During the right-sided HC the pressures in
the right atrium, right ventricle, and pulmonary artery and
in wedge position were obtained and cardiac output and
pulmonary vascular resistance (PVR) calculated with the
use of the Fick method. In 88 patients, CPX was per-
formed; 14 patients were either not able or refused to undergo
this procedure. All data points from the beginning of the
exercise up to the ventilatory anaerobic threshold (VAT)
were used to calculate the VE/VCO2 slope.9,10 Furthermore,
if the determination of the VAT was difficult in the VE/
VCO2 slope, the VAT was also determined in the slope of
the exhaled CO2.11 Peak VO2 and respiratory quotient (RQ)
ratio were measured.
Statistical Analysis
The patient population was divided into tertiles based on
the VE/VCO2 slope. Data are presented as median (interquartile
range [IQR]) for nonnormally distributed data and as mean
± SD for normally distributed data or percentages. Differ-
ences between categoric groups were calculated with the use
of the chi-square test. Differences between continuous vari-
ables were calculated with the use of the Kruskal-Wallis
equality-of-populations rank test or 1-way analysis of vari-
ance where appropriate. To determine the factors relating to
the VE/VCO2 slope, a univariate linear regression model was
performed. We performed one multivariable linear regres-
sion analysis with backward elimination including variables
that showed a P value of <.1 in univariate analyses. Kaplan-
Meier curves were constructed to determine the mortality in
the 3 VE/VCO2 tertiles with the use of the log-rank test of
equality. Univariate and multivariable Cox proportional hazard
regression models were used to calculate the predictive value
of the VE/VCO2 slope on a continuous scale and by tertiles
on mortality. The proportional hazard assumption was checked
by investigation of Schoenfeld residuals, and no violations
were observed. A P value of <.05 was considered to be sta-
tistically significant. Analyses were conducted with the use




The baseline characteristics according to tertiles of VE/
VCO2 slope are presented in Table 1. In all patients, the mean
age was 73 ± 9 years and 67% were female. The lowest tertile
(25.0–33.0) and middle tertile (33.1–38.3) of VE/VCO2 slope
each consisted of 29 patients, and the highest tertile (38.4–
89.0) consisted of 30 patients. Mean age did not differ among
the 3 groups. The NYHA functional class did not differ among
the tertiles (P = .064). NT-proBNP plasma levels were
599.5 ng/L (IQR 312.0–989.0) in the lowest tertile, 930 ng/L
in the middle tertile (461–1615), and 1561 ng/L in the highest
tertile (535.5–2479.0; P = .037). A subdivision of patients with
and without atrial fibrillation was analyzed, and no differ-
ences were observed in that analysis regarding the VE/
VCO2 slope (P = .924).
Results of the peak VO2 are presented in Table 2. Peak VO2
did not differ among the VE/VCO2 slope tertiles (P = .150).
Interestingly, only 31 patients (35%) reached an RQ ratio of
≥1. The RQ ratio did not differ among tertiles.
Baseline invasive hemodynamic measurement results across
the VE/VCO2 slope tertiles are presented in Table 3. The lowest
right ventricular systolic pressure (46 ± 15 mm Hg) was found
in the lowest VE/VCO2 slope tertile, and right ventricular sys-
tolic pressure was highest (57 ± 19 mm Hg) in the highest
tertile (P = .011). Mean pulmonary artery pressure (mPAP)
was highest (35 ± 12 mm Hg) in the highest tertile, was
29 ± 7 mm Hg in the middle tertile, and was lowest
(29 ± 10 mm Hg) in the lowest tertile (P = .017).
778 Journal of Cardiac Failure Vol. 23 No. 11 November 2017
Correlation Among Baseline Parameters and the
VE/VO2 Slope in HFpEF
Results of the univariate and multivariable regression anal-
yses are presented in Table 4. Multiple significant correlations
were observed between invasively measured pressures and
the VE/VO2 slope. mPAP was correlated with the VE/VCO2
slope: correlation coefficient (CE) = 0.287; P = .002. When
adjusted for age and log NT-proBNP, mPAP was still corre-
lated with the VE/VCO2 slope: CE = 0.233; P = .027. Even
so, PVR was correlated with the VE/VCO2 slope when ad-
justed for age and log NT-proBNP levels: CE = 0.015; P = .024.
No correlation was observed between pulmonary capillary
wedge pressure and the VE/VCO2 slope: CE = 0.061; P = .704.
After stepwise multivariable regression analysis of the inva-
sive hemodynamic and the clinical variables with backward
elimination, the only variable that remained independently
associated with VE/VCO2 slope was PVR.
The correlation between baseline parameters or invasively
measured pressures and peak VO2 could not be interpreted,
because, as mentioned above, only 35% of the patients reached
an RQ ≥1.
Survival Analysis
Sixteen (18%) patients died during a mean follow-up time
of 2 ± 1 years. Increased VE/VCO2 slope tertiles showed a
Table 1. Baseline Characteristics
Characteristic Total
VE/VCO2 slope tertitle
P ValueLowest Middle Highest
n 88 29 29 30
VE/VCO2 25.0–33.0 33.1–38.3 38.4–89.0
Age (y) 73 ± 9 73.3 ± 7.4 74.8 ± 8.4 71.7 ± 11.0 .430
Sex, male (%) 33 45 17 37 .071
NYHA functional classification (%) .064
II 41 55 45 23
III 57 45 55 70
LVEF (%) 60.0 (55.0–60.0) 60.0 (55.0–60.0) 60.0 (57.5–60.0) 60.0 (55.0–60.0) .540
SBP (mm Hg) 151.0 (134.0–165.0) 152.5 (140.5–161.0) 154.0 (135.0–171.0) 144.5 (128.0–162.0) .270
DBP (mm Hg) 68.0 (60.0–78.0) 68.0 (63.0–73.5) 69.0 (60.0–79.0) 64.5 (56.0–79.0) .720
Heart rate (beats/min) 71 ± 12 69 ± 12 70 ± 13 74 ± 11 .230
Body mass index (kg/m2) 27 (25–31) 27.5 (24.7–33.2) 27.1 (25.0–30.7) 26.3 (24.2–29.4) .350
Heart rhythm .480
SR (%) 58 66 55 53 .600
AF (%) 33 24 38 37 .460
Medical history (%)
Cerebrovascular disease 3 7 3 0 .340
AF 51 55 48 50 .860
Chronic 35 28 45 33 .380
Paroxysmal 17 28 7 17 .110
Diabetes mellitus 28 24 28 33 .730
Hypertension 65 69 62 63 .840
COPD 16 14 17 17 .930
Pacemaker 11 10 10 13 .920
Medical therapy (%)
β-Blocker 78 76 90 70 .170
Diuretic 75 61 76 87 .074
ACE inhibitor 68 64 76 63 .520
Aldosterone blocker 30 21 31 37 .440
Calcium channel blocker 5 4 3 7 .800
Hemoglobin (mmol/L) 8.2 (7.5–8.6) 8.3 (7.8–8.7) 8.1 (7.5–8.6) 8.1 (7.1–8.7) .680
Creatinine (µmol/L) 98.4 ± 37.9 96.2 ± 39.6 89.1 ± 26.4 110.6 ± 44.1 .097
eGFR (mL/min) 61.0 (44.0–73.0) 65.0 (52.0–77.0) 61.0 (45.0–78.0) 50.0 (32.0–68.0) .260
Urea (mmol/L) 9.1 ± 4.5 7.6 ± 3.1 8.6 ± 4.1 11.2 ± 5.3 .006
Plasma NT-proBNP (ng/L) 840 (411–1938) 599.5 (312.0–989) 930 (461–1615) 1561 (535.5–2479) .037
Sodium (mmol/L) 141 (138–143) 142.0 (139.5–144.0) 140.5 (138.0–142.0) 140.0 (137.0–142.0) .120
Potassium (mmol/L) 4.2 (3.9–4.6) 4.3 (3.9–4.6) 4.2 (4.0–4.7) 4.2 (3.9–4.5) .750
Mortality during follow-up (%) 18 14 14 30 .189
Normally distributed data are presented as mean ± SD, nonnormally distributed data as median (interquartile range), categoric variables as percentages of
observations. VE/VCO2, ventilatory equivalent for carbon dioxide; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; SBP, sys-
tolic blood pressure; DBP, diastolic blood pressure; SR, sinus rhythm; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-
converting enzyme; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro–B-type natriuretic peptide.











n 29 29 30
Peak VO2 14 ± 4 12 ± 3 12 ± 4 .150
RQ 0.96 ± 0.13 0.94 ± 0.11 0.91 ± 0.11 .436
RQ ≥1 (%) 35 38 33 .891
VE/VCO2, ventilatory equivalent for carbon dioxide; VO2, oxygen
consumption.
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trend toward increased mortality (P = .076). No differences
were observed among the peak VO2–based tertiles (P = .783).
In univariable analyses, the increase of VE/VCO2 showed
a significant increase risk for all-cause mortality (hazard ratio
[HR] 1.92 [per 10 increase], 95% confidence interval [CI]
1.34–2.74; P < .001; Table 5). an association that was unaf-
fected by adjustment for age and sex. When adjusted for
independent predictors of outcome, including age, sex, PAP,
renal function, NT-proBNP plasma levels, and atrial fibril-
lation, VE/VCO2 slope was independently associated with an
increased risk for all-cause mortality: HR 1.74 (per 10 in-
crease), 95% CI 1.03–2.94; P = .040. When the same analysis
was performed on peak VO2, no association with all-cause
mortality in either univariate (Table 5) or multivariable anal-
ysis was found: multivariable HR 1.42, 95% CI 0.39–5.24;
P = .600).








n 88 29 29 30
RAM (mm Hg) 8.4 ± 4.9 7.6 ± 4.7 8.3 ± 4.2 9.3 ± 5.7 .380
RVS (mm Hg) 50.0 ± 16.5 46.3 ± 15.3 46.0 ± 11.2 57.2 ± 19.5 .011
RVED (mm Hg) 9.2 ± 4.5 8.3 ± 4.7 9.6 ± 3.4 9.7 ± 5.1 .380
sPAP (mm Hg) 49.0 ± 16.4 46.0 ± 15.7 44.7 ± 10.6 55.9 ± 19.5 .014
dPAP (mm Hg) 18.1 ± 6.9 16.7 ± 6.7 17.1 ± 5.5 20.3 ± 8.0 .088
mPAP (mm Hg) 31.0 ± 10.2 28.9 ± 9.8 28.7 ± 7.2 35.2 ± 11.7 .017
PH 65 (74) 19 (66) 22 (76) 24 (80) .429
PCWP (mm Hg) 17.4 ± 6.1 16.0 ± 5.7 17.4 ± 5.3 18.8 ± 6.9 .210
PCWPdi 65 (74) 19 (66) 21 (72) 25 (83) .291
LVS (mm Hg) 152.2 ± 22.2 153.9 ± 19.8 158.4 ± 22.4 144.1 ± 22.5 .056
LVED (mm Hg) 16.6 ± 5.8 15.1 ± 6.0 17.1 ± 5.1 17.5 ± 6.2 .310
AOS (mm Hg) 149.1 ± 22.6 151.6 ± 21.0 152.9 ± 23.6 143.2 ± 22.6 .210
AOD (mm Hg) 69.1 ± 12.8 70.3 ± 11.5 70.2 ± 13.1 67.1 ± 13.8 .570
AOM (mm Hg) 100.6 ± 14.3 101.7 ± 11.7 103.0 ± 16.1 97.1 ± 14.5 .250
PVR (dyne·s/cm5) 212 ± 161 190 ± 156 175 ± 93 264 ± 201 .078
Normally distributed data are presented as mean ± SD, and categoric variables as n (%). RAM, mean right atrial pressure; RVS, right ventricular systolic
pressure; RVED, right ventricular end-diastolic pressure; sPAP, systolic pulmonary artery pressure; dPAP, diastolic pulmonary arterial pressure; mPAP, mean
pulmonary arterial pressure; PH, pulmonary arterial hypertension; PCWP, mean pulmonary capillary wedge pressure; PCWPdi, PCWP as dichotomous vari-
able, >16 cutoff; LVS, left ventricular systolic pressure; LVED, left ventricular end-diastolic pressure; AOS, aortic systolic pressure; AOD, aortic diastolic
pressure; AOM, aortic mean pressure; PVR, pulmonary vascular resistance.
Table 4. Regression: Correlation With the VE/VCO2 Slope
Univariate
Correlation
Coefficients P Value Model 1 P Value
mPAP 0.287 .002 0.233 .027
sPAP 0.172 .003 0.134 .042
PVR 0.019 .002 0.015 .024
RVS 0.175 .002 0.134 .041
LVS −0.123 .008 −0.107 .030
Sodium −0.494 .092 – –
Diuretic use 3.723 .091 – –
Log NT-proBNP 0.917 .127 – –
NYHA functional class 2.873 .145 – –
Log urea 2.111 .173 – –
Age −0.130 .222 – –
Sex −2.084 .308 – –
β-Blocker use 0.453 .847 – –
LVED −0.160 .281 – –
PCWP 0.061 .704 – –
Model 1: adjusted for log NT-proBNP and age. Abbreviations as in Tables
1 and 3.
Table 5. Cox Regression Analysis
Variable
Univariate Multivariable
HR (95% CI) P Value HR (95% CI) P Value
VE/VCO2
Continuous (per 10 increase) 1.92 (1.34–2.74) <.001 2.04 (1.42–2.93) <.001
Lowest tertile Ref – Ref –
Middle tertile 1.44 (0.32–6.52) .630 1.26 (0.28–5.82) .760
Highest tertile 3.57 (0.96–13.3) .060 4.11 (1.09–15.46) .040
Peak VO2
Continuous (per 5 mL·min−1·kg−2 decrease) 3.53 (1.29–9.62) .014 3.49 (1.26–9.69) .017
Highest tertile REF — REF —
Middle tertile 0.97 (0.21–4.39) .960 0.96 (0.21–4.36) .950
Lowest tertile 3.03 (0.78–11.8) .110 2.93 (0.74–11.6) .130
Model 1: adjusted for age and sex. Abbreviations as in Table 2.
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Discussion
This study shows that increased VE/VCO2 slope, estab-
lished from submaximal exercise testing, is related to more
severe disease and higher intracardiac and intrapulmonary pres-
sures and had an independent association with increased
mortality in patients with HFpEF and pulmonary hyperten-
sion. These associations were not found with peak VO2, which
was frequently not reached in these patients, as evidencde by
an RQ <1.0 in 65% of the patients.
Although the mechanisms behind HFpEF are not fully un-
derstood, the main symptoms of the patients are shortness of
breath and impaired exercise tolerance. These symptoms are
not very specific for HFpEF. We therefore tried to identify
independent predictors of the exercise capacity in HFpEF pa-
tients. Peak VO2 is the criterion standard in CPX, so peak
VO2 is often used as the main parameter in exercise toler-
ance studies in HF.12,13 Peak VO2 depends on heart rate, stroke
volume, and arterial-mixed venous oxygen content differ-
ence (C[a-v]O2). Each of these 3 parameters, however, has
been shown to be of limited use in HFpEF patients.14 A re-
liable peak VO2 measurement can be achieved only when
patients perform at the maximum of their cardiopulmonary
capacity, ie, achieve an RQ ratio ≥1.5 However, most of the
peak VO2 measurements in our study were not reliable, because
the RQ ratio ≥ 1 was not reached.15 It should be noted that
we included an elderly population with multiple comorbidities
and with severe HFpEF with evidence of increased PAPs. In
this elderly and diseased population, VE/VCO2 slope was ideal
to study exercise capacity even when peak VO2 was not
reached. VE versus VCO2 is a linear relationship in incre-
mental exercise. In the final phase of exercise, oxygen supply
to the tissue is not sufficient and blood lactate concentration
increases at a steep rate. At that point, the VAT, excess CO2
is produced which results in a steeper bend of the VE/
VCO2 slope.16 The linear relationship up to the VAT is a reliable
measure for exercise capacity in HF patients because pa-
tients do not need to reach their maximum exercise capacity.16,17
A few studies have shown that increased VE/VCO2 is as-
sociated with increased mortality in patients with HFrEF.18
An overview by Guazzi described a solid base for the hy-
pothesis that the VE/VCO2 slope might be of prognostic value
in HFpEF patients.19 However, this is the 1st study on clin-
ical and hemodynamic correlates and prognostic value of VE/
VCO2 slope specifically in patients with HFpEF. A few others
studied the value of CPX in patients with HFpEF.20–22 Guazzi
et al compared CPX parameters with multiple variables
between an HFrEF and an HFpEF population.20 Although that
study showed that the VE/VCO2 slope represents HFpEF se-
verity, no relationship between the VE/VCO2 slope and
mortality was studied. Cahalin et al studied the prognostic
relevance of heart rate recovery after a 6-minute walk test in
patients with HFrEF (n = 216) and HFpEF (n = 42). They
showed that in the combined population with predomi-
nantly HFrEF patients, the VE/VCO2 slope was a significant
prognostic parameter in the 6-minute walk test, and they found
that the VE/VCO2 slope was the only predictor of major
cardiac events.21 Nedeljkovic et al studied the value of CPX
as a diagnostic tool for HFpEF. They concluded that the VE/
VCO2 slope could be a reliable test to diagnose HFpEF in
an early stage, but they did not investigate the possible as-
sociation between VE/VCO2 and mortality.22
Hemodynamic measurements in our study showed that in-
creased VE/VCO2 slope was associated with increased mPAP
and PVR. Of note, no association was observed between VE/
VCO2 slope and PWCP. The VE/VCO2 slope seems to be
determined mostly by PAP and PVR and not PWCP. Guazzi
et al also described a correlation between increased systolic
PAP and a poorer VE/VCO2 slope.20 However, in contrast with
Guazzi et al, we did not find a correlation between the
echocardiographic parameters LVEF and E/E′ ratio and VE/
VCO2 slope. We hypothesize that this difference can be
explained by the fact that our population was a more typical
HFpEF population: older, mostly female, with higher levels
of NT-proBNP and more severe HF. Differences in etiology
of HFpEF can be seen between men and women: generally
men are more prone to develop ischemic HF, in contrast to
women where the abundance of comorbidities is seen as
causing HFpEF.23,24
Study Limitations
The retrospective nature of this study is a limitation, and
the relative small group size resulted in limited possibilities
for multivariate analysis. Also, despite the predefined hy-
pothesis to determine the diagnostic value of the VE/VCO2
slope, the subanalyses were at risk of multiple testing un-
certainties. To limit this risk, the multivariable regression
analysis was performed with backward elimination. This study
was not ideal for comparing peak VO2 and VE/VCO2 slope,
because few patients reached an RQ ratio >1. A strong point
of this study is the well defined HFpEF population and
the simultaneously performed right-sided HC and
echocardiography. However, these patients also showed
echocardiographic signs of pulmonary hypertension, so the
results cannot be extrapolated to the general HFpEF population.
Conclusion
In elderly patients with HFpEF, increased PAPs, and mul-
tiple comorbidities, peak VO2 could often not be reached. In
these patients, increased VE/VCO2 slope (and not peak VO2)
was associated with more severe disease and higher intra-
cardiac and intrapulmonary pressures and was independently
associated with increased mortality.
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